Proton Pump Inhibitor (PPI) Lawsuit
(Kidney Disease & Kidney Failure)
Federal litigation against manufacturers of heartburn medications alleging PPIs like Prilosec, Nexium, and Prevacid caused serious kidney injuries including chronic kidney disease, acute kidney injury, and end-stage renal disease without adequate warnings.
Key Takeaways
- Over 11,300 cases pending as of May 2026 with 39% resolved
- JAMA study found 50% higher risk of chronic kidney disease in PPI users
- FDA issued warnings for bone fractures, magnesium deficiency, and C. diff infections
- Defendants include AstraZeneca (Prilosec, Nexium), Takeda (Prevacid), Pfizer/Wyeth (Protonix)
- Mature MDL with steady case resolution through settlements and dismissals
Key Facts (May 2026)
| Pending Actions | 11,322 cases in federal MDL |
| Total Actions Filed | 18,706 cases (historical) |
| Key Defendants | AstraZeneca, Takeda Pharmaceuticals, Pfizer/Wyeth, Procter & Gamble |
| Presiding Judge | Hon. Claire C. Cecchi (D. New Jersey) |
| MDL Created | August 2017 |
| JAMA Study (2016) | 50% higher risk of chronic kidney disease in PPI users (HR 1.50) |
| FDA Warnings Issued | Bone fractures (2010), Hypomagnesemia (2011), C. diff (2012) |
| Can You Still File? | Limited — most new cases focus on severe kidney injuries |
Case Resolution Progress
This mature MDL shows steady case resolution through settlements and dismissals. 653 cases have been resolved since January 2025.
Source: JPML MDL Statistics Reports, January 2025-May 2026
JAMA Internal Medicine Study (2016)
A landmark multicenter study examining 10,482 participants from the ARIC study and 248,751 patients from the Geisinger Health System found significant kidney risks:
Source: Lazarus B, et al. JAMA Intern Med. 2016;176(2):238-246 (PMID: 26752337)
1 What Are Proton Pump Inhibitors?
Proton pump inhibitors (PPIs) are among the most widely prescribed medications in the United States, used to treat heartburn, acid reflux, GERD, peptic ulcers, and Barrett's esophagus. According to FDA data, approximately 21 million patients filled PPI prescriptions at outpatient retail pharmacies in 2009 alone.
PPIs work by irreversibly inhibiting the hydrogen-potassium ATPase enzyme (the "proton pump") in gastric parietal cells. This mechanism reduces stomach acid production more completely and for longer periods than H2 receptor antagonists like famotidine (Pepcid).
2 Alleged Kidney Injuries
Plaintiffs allege PPI manufacturers knew or should have known about serious kidney risks but failed to adequately warn patients and healthcare providers.
Chronic Kidney Disease (CKD)
Progressive, long-term loss of kidney function. The 2016 JAMA study found PPI users had a 50% higher risk of developing CKD, with risk increasing based on dosage and duration.
A separate VA study (Xie et al., 2016) found HR 1.28 for incident CKD and HR 1.96 for ESRD.
Acute Kidney Injury (AKI)
Sudden decline in kidney function occurring over hours to days. AKI can occur even with shorter-term PPI use and may require hospitalization or dialysis.
Acute Interstitial Nephritis (AIN)
Inflammation of the kidney tubules and surrounding tissue. AIN has been linked to PPIs since the 1990s and is an established adverse effect documented in medical literature.
End-Stage Renal Disease (ESRD)
Complete kidney failure requiring dialysis or transplantation. The VA study found PPI users had nearly double the risk (HR 1.96) of progressing to ESRD.
Source: Xie et al., J Am Soc Nephrol. 2016 (PMID: 27080976)
Other FDA-Documented Risks
FDA issued Drug Safety Communications for these risks in 2010-2012.
3 Products Involved in the Litigation
| Brand Name | Generic Name | Manufacturer | FDA Approved |
|---|---|---|---|
| Prilosec | Omeprazole | AstraZeneca | Sept 1989 |
| Prevacid | Lansoprazole | Takeda | May 1995 |
| Protonix | Pantoprazole | Pfizer/Wyeth | Feb 2000 |
| Nexium | Esomeprazole | AstraZeneca | Feb 2001 |
| Aciphex | Rabeprazole | Eisai/Janssen | Aug 1999 |
| Dexilant | Dexlansoprazole | Takeda | Jan 2009 |
Prescription PPIs
Used for longer durations at higher doses to treat GERD, peptic ulcers, H. pylori eradication, Zollinger-Ellison syndrome, and NSAID-induced ulcer prevention.
OTC PPIs
Prilosec OTC, Prevacid 24HR, Nexium 24HR — marketed at lower doses for 14-day courses, up to 3 times per year. FDA notes consumers often exceed these directions.
4 FDA Warnings & Regulatory Timeline
First PPI approved in the United States, ushering in a new class of acid-suppression medications.
First PPI available over-the-counter, dramatically expanding patient access without physician oversight.
FDA warns of increased risk of hip, wrist, and spine fractures with high-dose or long-term PPI use. Studies showed odds ratios up to 2.65 for hip fractures.
FDA warns prescription PPIs may cause low magnesium levels with prolonged use (usually >1 year), potentially causing tetany, arrhythmias, and seizures.
FDA warns of increased risk of C. difficile-associated diarrhea. Studies showed 1.4-2.75x higher risk among PPI users.
Lazarus et al. publish landmark study finding 50% higher risk of chronic kidney disease in PPI users (PMID: 26752337).
Xie et al. publish VA study finding nearly double the risk of end-stage renal disease (HR 1.96) in PPI users vs. H2 blocker users (PMID: 27080976).
JPML creates PPI kidney injury MDL in the District of New Jersey under Judge Claire C. Cecchi.
5 Do You Qualify for Compensation?
You may be eligible to file a claim if you meet these criteria:
Eligibility Requirements
- Took a PPI medication — Prilosec, Nexium, Prevacid, Protonix, Dexilant, Aciphex, or generic equivalents
- Extended use period — Typically 6+ months, though acute injury claims may qualify with shorter use
- Diagnosed with kidney disease — CKD, AKI, acute interstitial nephritis, ESRD, or need for dialysis
- No pre-existing kidney problems — Or kidney condition worsened after starting PPIs
- Medical documentation — Records showing PPI prescriptions/use and kidney disease diagnosis
6 Frequently Asked Questions
How long do I need to have taken PPIs to qualify?
Does it matter if I used OTC or prescription PPIs?
What is MDL "No. II" — was there a previous PPI MDL?
Why hasn't the FDA issued a kidney warning for PPIs?
Have any settlements been reached?
What do plaintiffs need to prove?
Sources & References
8 official sources cited• Judicial Panel on Multidistrict Litigation (JPML) — Official MDL Statistics (January 2026)
• Lazarus B, et al. "Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease." JAMA Intern Med. 2016;176(2):238-246 (PMID: 26752337)
• Xie Y, et al. "Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD." J Am Soc Nephrol. 2016;27(10):3153-3163 (PMID: 27080976)
• FDA Drug Safety Communication — Bone fracture risk (May 2010, updated March 2011)
• FDA Drug Safety Communication — Low magnesium levels (March 2011)
• FDA Drug Safety Communication — C. difficile infection risk (February 2012)
• FDA Drugs@FDA Database — Drug approval histories (NDA 019810, 020406, 020987, 021153)
• NIDDK — Treatment for GER & GERD information
Attorney Advertising. The information on this page is provided for general informational purposes only and does not constitute legal advice. No attorney-client relationship is created by accessing or using this content.
Every case is unique, and results depend on the specific facts and circumstances involved. Past settlement amounts and case outcomes do not guarantee similar results in your case. If you believe you have a legal claim, you should consult with a licensed attorney in your jurisdiction who can evaluate your specific situation.